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Metabolic syndrome (MetS) is a major risk factor of cardiovascular disease. Over the
past decade compelling evidence has been collected suggesting a unique depot of adipose
tissue called perivascular adipose tissue (PVAT) plays an active roll in vascular function.
PVAT is known to release a multitude of vaso-active substances. Just like endothelium,
PVAT produces nitric oxide (NO) from the enzyme endothelium nitric oxide synthase
(eNOS). In order for eNOS to function properly it must be coupled in a homo-dimer
configuration assisted by the co-factor tetrahydrobiopterin (BH4). A three-step process
produces BH4 locally with GTP-cyclohydrolase-1 (Gch1) catalyzing the rate-limiting
step. The production of NO from the PVAT surrounding the aorta may contribute
directly to vascular tone. Furthermore other factors release from PVAT may effect aortic
endothelium’s production of nitric oxide. PURPOSE: To show MetS causes a disruption
in normal expression of eNOS and its cofactor BH4 causing a decrease in PVAT derived
NO. Further, to reveal healthy PVAT exudate augments endothelium NO production
while obese PVAT exudate blunts endothelium NO production. METHODS: Lean
(LZR) and Obese (OZR) Zucker Rats were utilized for our model of health and MetS.
PVAT expression for eNOS and BH4 were measured by qPCR. NO bioavailability was
assessed using a DAF-FM diacetate assay. RESULTS: Similar to previous findings in
visceral adipose, MetS caused an up-regulation of eNOS, 1.8 fold increase in OZR from
LZR (p≤ 0.001). However, this was accompanied by a 1.6 fold decrease in Gch1
expression in OZR (p≤ 0.001). NO production from OZR PVAT was decreased 36% (p
≤ 0.01). Aortic ring segments treated with exudate from the surrounding PVAT caused a
relative 20% increase of NO in LZR and a 20% decrease in OZR. PVAT treated aortic
rings from OZR had a 54% decrease in relative NO release (p ≤ 0.001).
CONCLUSIONS: MetS decreases PVAT released NO despite an increase in eNOS
expression. This may be attributed to the mismatched expression of Gch1, which may
lead to a lower BH4, greater uncoupling of PVAT eNOS, and reactive oxygen species
production. Furthermore PVAT exudate treatment had opposite effects on endothelium
NO production. This decrease in bioavailable NO may contribute to the greater aortic
tone associated with MetS.
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